Introduction: Balloon angioplasty can be a requisite approach for the treatment of symptomatic and/or severe vasospasm. Dual-lumen microcatheter balloons have multiple potential advantages for this indication including accommodating a 0.014-inch wire and the potential to deliver superselective vasodilators directly via the microcatheter prior to angioplasty. Methods: The authors reviewed a 3-year institutional experience with the Scepter XC balloon (Microvention, Tustin, CA, USA) in the treatment of postaneurysmal subarachnoid hemorrhage vasospasm, focusing on treatment methods, angiographic, and clinical results. Results: Sixty-four vessels were treated in 18 patients. Fifteen cases were performed under intravenous (i.v.) conscious sedation (83%). The mean pretreatment stenosis was 59% (range 40-80), and the mean post-treatment stenosis was 12% (range 0-40). Five vessels in 3 patients were subsequently retreated via angioplasty for recurrent vasospasm (8%). There were no complications related to the passage of the balloon microcatheter or inflation of the balloon such as dissection or vessel rupture. Of 14 patients with delayed cerebral ischemia, 7 had complete symptomatic resolution after treatment, and 3 had significant symptomatic improvement. Four patients did not improve after treatment though 3 already had confirmed infarcts on imaging prior to angiography. Conclusion: The Scepter XC is a safe and effective balloon microcatheter for angioplasty of cerebral vasospasm after subarachnoid hemorrhage, allowing for superselective delivery of a vasodilator. Its ease of deliverability and visibility often allows for the performance of the procedure under i.v. conscious sedation.

Keywords:
Vasospasm, Angioplasty, Balloon, Aneurysm, Subarachnoid hemorrhage, Ischemia, Stroke
1.
Connolly ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, Hoh BL, Kirkness CJ, Naidech AM, Ogilvy CS, Patel AB, Thompson BG, Vespa P: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43:1711-1737.
2.
Kassell NF, Sasaki T, Colohan AR, Nazar G: Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985;16:562-572.
3.
Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL: The international cooperative study on the timing of aneurysm surgery: Part 1 - Overall management results. J Neurosurg 1990;73:18-36.
4.
Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP: Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1982;11:337-343.
5.
Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS, Rordorf GA: Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol 2004;25:819-826.
6.
Feng L, Fitzsimmons BF, Young WL, Berman MF, Lin E, Aagaard BD, Duong H, Pile-Spellman J: Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. AJNR Am J Neuroradiol 2002;23:1284-1290.
7.
Rosenwasser RH, Armonda RA, Thomas JE, Benitez RP, Gannon PM, Harrop J: Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options. Neurosurgery 1999;44:975-979.
8.
Eskridge JM, McAuliffe W, Song JK, Deliganis AV, Newell DW, Lewis DH, Mayberg MR, Winn HR: Balloon angioplasty for the treatment of vasospasm: results of first 50 cases. Neurosurgery 1998;42:510-516.
9.
Higashida RT, Halbach VV, Dowd CF, Dormandy B, Bell J, Hieshima GB: Intravascular balloon dilatation therapy for intracranial arterial vasospasm: patient selection, technique and clinical results. Neurosurg Rev 1992;15:89-95.
10.
Linskey ME, Horton JA, Rao GR, Yonas H: Fatal rupture of the intracranial carotid artery during transluminal angioplasty for vasospasm induced by subarachnoid hemorrhage. J Neurosurg 1991;74:985-990.
11.
Spiotta AM, Miranpuri A, Hawk H, Chaudry MI, Turk AS, Turner RD: Balloon remodeling for aneurysm coil embolization with the coaxial lumen Scepter C balloon catheter: initial experience at a high volume center. J Neurointervent Surg 2013;5:582-585.
12.
Jagadeesan BD, Grigoryan M, Hassan AE, Grande AW, Tummala RP: Endovascular balloon-assisted embolization of intracranial and cervical arteriovenous malformations using dual lumen co-axial balloon microcatheters and Onyx: initial experience. Neurosurgery 2013;73(suppl 2):ons238-ons243.
13.
Paramasivam S, Niimi Y, Fifi J, Berenstein A: Onyx embolization using dual-lumen balloon catheter: initial experience and technical note. J Neuroradiol 2013;40:294-302.
14.
Spiotta AM, James RF, Lowe SR, Vargas J, Turk AS, Chaudry MI, Bhalla T, Janjua RM, Delaney JJ, Quintero-Wolfe S, Turner RD: Balloon-augmented Onyx embolization of cerebral arteriovenous malformations using a dual-lumen balloon: a multicenter experience. J Neurointervent Surg 2015;7:721-727.
15.
Ladner TR, He L, Davis BJ, Yang GL, Wanna GB, Mocco J: Initial experience with dual-lumen balloon catheter injection for preoperative embolization of skull base paragangliomas. J Neurosurg 2016;124:1813-1819.
16.
Ladner TR, He L, Lakomkin N, Davis BJ, Cheng JS, Devin CJ, Mocco J: Minimizing bleeding complications in spinal tumor surgery with preoperative Onyx embolization via dual-lumen balloon catheter. J Neurointervent Surg 2016;8:210-215.
17.
Heit JJ, Choudhri O, Marks MP, Dodd RL, Do HM: Cerebral angioplasty using the Scepter XC dual lumen balloon for the treatment of vasospasm following intracranial aneurysm rupture. J Neurointervent Surg 2015;7:56-61.
18.
Seby J, Spiotta AM, Turner RM, Chaudry MI, Turk AS, Hui F: Initial experience with the coaxial dual-lumen Scepter C balloon catheter for endovascular management of cerebral vasospasm from subarachnoid hemorrhage. J Neurointervent Surg 2014;6:125-128.
19.
Charpentier C, Audibert G, Guillemin F, Civit T, Ducrocq X, Bracard S, Hepner H, Picard L, Laxenaire MC: Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage. Stroke 1999;30:1402-1408.
20.
Gruber A, Ungersböck K, Reinprecht A, Czech T, Gross C, Bednar M, Richling B: Evaluation of cerebral vasospasm after early surgical and endovascular treatment of ruptured intracranial aneurysms. Neurosurgery 1998;42:258-267.
21.
Dumont AS, Crowley RW, Monteith SJ, Ilodigwe D, Kassell NF, Mayer S, Ruefenacht D, Weidauer S, Pasqualin A, Macdonald RL: Endovascular treatment or neurosurgical clipping of ruptured intracranial aneurysms: effect on angiographic vasospasm, delayed ischemic neurological deficit, cerebral infarction and clinical outcome. Stroke 2010;41:2159-2524.
22.
Gross BA, Lai PMR, Frerichs KU, Du R: Treatment modality and vasospasm after aneurysmal subarachnoid hemorrhage. World Neurosurg 2014;82:e725-e730.
23.
Gnanalingham KK, Apostolopoulos V, Barazi S, O'Neill K: The impact of the international subarachnoid aneurysm trial (ISAT) on the management of aneurysmal subarachnoid haemorrhage in a neurosurgical unit in the UK. Clin Neurol Neurosurg 2006;108:117-123.
24.
Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R: International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002;360:1267-1274.
25.
Miley JT, Tariq N, Souslian F, Qureshi N, Suri MF, Tummala RP, Vazquez G, Qureshi AI: Comparison between angioplasty using compliant and noncompliant balloons for treatment of cerebral vasospasm associated with subarachnoid hemorrhage. Neurosurgery 2011;69(suppl 2):ons161-ons168.
26.
Patel A, Griessenauer CJ, Gupta R, Adeeb N, Foreman PM, Shallwani H, Moore JM, Harrigan MR, Siddiqui AH, Ogilvy CS, Thomas AJ: Safety and efficacy of noncompliant balloon angioplasty for the treatment of subarachnoid hemorrhage-induced vasospasm: a multicenter study. World Neurosurg 2017;98:189-197.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.